ClinicalTrials.gg
CompletedNCT02139046Updated Nov 3, 2016Results posted

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

A Phase 3 interventional study of Febuxostat IR and Febuxostat XR in Gout, sponsored by Takeda. Completed at 192 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,790
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
2nd of 29
1,790 · median 109
Started
2014
with 3 others
Phase 3
10 of 29
none open now
Registered
20th of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 2nd largest by enrollment, is one of 4 that started in 2014, is one of 10 in phase 3, and was the 20th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.

Read the detailed description

The drug being tested in this study is called febuxostat. Febuxostat is being tested to decrease and maintain serum urate in people who have gout. This study will look at serum urate levels in people who take febuxostat extended release (XR) capsules compared to febuxostat immediate release (IR) capsules and placebo.

The study will enroll approximately 1750 patients. Participants will be randomly assigned (by chance) to one of the five treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Febuxostat 40 mg XR
  • Febuxostat 80 mg XR
  • Febuxostat 40 mg IR
  • Febuxostat 80 mg IR
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient.

All participants will be asked to take one capsule at the same time each day throughout the study, and will be asked to call an interactive voice response system any time they are having a gout flare up. In addition to study medication, participants will also take 0.6 mg of colchicine every day or every other day, or naproxen 250 mg twice a day and lansoprazole 15 mg once a day to prevent gout flare ups.

This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to approximately 4 months and participants will make up to 7 visits to the clinic.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedure.
  3. Has a history or presence of gout defined as having one or more of the American Rheumatism Association (ARA) criteria for the diagnosis of gout:

    1. A tophus proven to contain urate crystals by chemical or polarized light microscopic means, AND/OR;
    2. Characteristic urate crystals in the joint fluid, AND/OR;
    3. History of at least 6 of the following clinical, laboratory, and x-ray phenomena:

    i. more than one attack of acute arthritis, ii. maximum inflammation developed within 1 day, iii. monoarticular arthritis, iv. redness observed over joints, v. first metatarsophalangeal joint painful or swollen, vi. unilateral first metatarsophalangeal joint attack, vii. unilateral tarsal joint attack, viii. tophus (proven or suspected), ix. Hyperuricemia, x. asymmetric swelling within a joint on x-ray, xi. subcortical cysts without erosions on x-ray; xii. joint fluid culture negative for organisms during attack.

  4. Is male or female at least 18 years of age, inclusive.
  5. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.
  6. Have a serum urate (sUA) level ≥8.0 mg/dL at the Day -4 Visit or at the retest visit.
  7. Has an estimated (eGRF) ≥15 mL/min using the Modification of Diet in Renal Disease (MDRD) formula at the Screening visit (Day -21 for participants on urate lowering therapy (ULT) and Day -4 for participants not on ULT) or at the retest visit.
  8. Has at least one gout flare within 12 months prior to Screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to Screening.
  2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  3. Is breastfeeding or pregnant.
  4. Has secondary hyperuricemia (eg, due to myeloproliferative disorder).
  5. Has a history of xanthinuria.
  6. Has received ULT (ie, allopurinol, probenecid, etc.) within 20 days prior to Day 1/Randomization Visit.
  7. Has a known to febuxostat or any components of their formulation; has a known hypersensitivity to naproxen, any other nonsteroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine or any components in their formulation.
  8. Has active peptic ulcer disease.
  9. Has a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the Screening Visit.
  10. Has (ALT) and aspartate aminotransferase (AST) values >2 x the (ULN).
  11. Has rheumatoid arthritis which requires treatment.
  12. Has a significant medical condition and/or conditions that would interfere with the treatment, safety, or compliance with the protocol.
  13. Has experienced a myocardial infarction (MI), stroke, hospitalized unstable angina, cardiac or cerebrovascular revascularization procedure or hospitalized (TIA) - except in participants who have severe renal impairment.
  14. Participants with severe renal impairment had a MI or stroke within 90 days prior to initial screening visit or has a MI or stroke during the screening period prior to Day 1/Randomization Visit.
  15. Participant consumes >14 alcoholic beverages/week. Has a history of alcoholism or illicit drug abuse within 5 years.
  16. Has participated in another investigational study within the 30 days prior to the Screening Visit.
  17. Has a known history of infection with , , or .
  18. Is required to take excluded medications.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,790 participants (actual)

Study arms

  • Active comparator
    Febuxostat IR 40 mg

    Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.

    Drug: Febuxostat IR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole

  • Active comparator
    Febuxostat IR 80 mg

    Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.

    Drug: Febuxostat IR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole

  • Experimental
    Febuxostat XR 40 mg

    Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.

    Drug: Febuxostat XR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole

  • Experimental
    Febuxostat XR 80 mg

    Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.

    Drug: Febuxostat XR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole

  • Placebo comparator
    Placebo

    Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.

    Drug: Febuxostat placebo · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole

Interventions

  • Febuxostat IR over-encapsulated tablets

    Also known as: Uloric

  • Febuxostat XR over-encapsulated capsules

    Also known as: Uloric

  • DrugFebuxostat placebo

    Febuxostat placebo-matching capsules

  • Colchicine tablets

  • Naproxen tablets

  • Lansoprazole capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3

    Time frame: Month 3

Secondary outcomes

  1. Percentage of Participants With at Least One Gout Flare Requiring Treatment

    A participant was considered to have a gout flare if the following criteria were met: Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare.

    Time frame: Baseline to Month 3

  2. Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3

    Time frame: Month 3

07

Results

Posted Nov 3, 2016

Participant flow

Participants took part in the study at 217 investigative sites in the United States from 18 April 2014 to 18 November 2015.

Participant flow — Overall Study
MilestonePlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
Started358359357358358
Safety analysis set356358355357357
Full analysis set357357355357357
Completed296305298290301
Not completed6254596857
Withdrew: Pretreatment event/adverse event9910137
Withdrew: Major protocol deviation91016126
Withdrew: Lost to follow-up1316161813
Withdrew: Voluntary withdrawal208101516
Withdrew: Lack of efficacy01212
Withdrew: Withdrawal due to a gout flare11101
Withdrew: Other miscellaneous reasons1094912

Outcome measures

PrimaryPercentage of Participants With Serum Urate <5.0 mg/dL at Month 3
Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3
percentage of participantsPlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
Percentage of Participants With Serum Urate <5.0 mg/dL at Month 30.315.725.942.650.1
Statistical analysis
  • Placebo vs Febuxostat XR 40 mg · Z-test · p = <0.001 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 25.6 · 95% CI 20.4 to 30.9Point estimates, confidence intervals, and p-values are presented using the Cui, Hung, and Wang (CHW) Z-test which accounts for the interim analysis.
  • Placebo vs Febuxostat XR 80 mg · Z-test · p = <0.001 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 49.8 · 95% CI 43.9 to 55.8Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 40 mg vs Febuxostat XR 40 mg · Z-test · p = 0.001 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 10.2 · 95% CI 3.5 to 17.0Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 80 mg vs Febuxostat XR 80 mg · Z-test · p = 0.043 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 7.5 · 95% CI -0.8 to 15.9Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
SecondaryPercentage of Participants With at Least One Gout Flare Requiring Treatment

A participant was considered to have a gout flare if the following criteria were met: Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare.

Time frame:
Baseline to Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Gout Flare Requiring Treatment
percentage of participantsPlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
Percentage of Participants With at Least One Gout Flare Requiring Treatment20.721.022.827.226.6
Statistical analysis
  • Placebo vs Febuxostat XR 40 mg · Z-test · p = 0.503 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 2.1 · 95% CI -4.9 to 9.0Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Placebo vs Febuxostat IR 80 mg · Z-test · p = 0.064 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 5.9 · 95% CI -1.2 to 13.0Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 40 mg vs Febuxostat XR 40 mg · Z-test · p = 0.561 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 1.8 · 95% CI -5.1 to 8.7Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 80 mg vs Febuxostat XR 80 mg · Z-test · p = 0.869 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: -0.5 · 95% CI -8.0 to 6.9Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
SecondaryPercentage of Participants With Serum Urate <6.0 mg/dL at Month 3
Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3
percentage of participantsPlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
Percentage of Participants With Serum Urate <6.0 mg/dL at Month 30.640.348.257.761.1
Statistical analysis
  • Placebo vs Febuxostat XR 40 mg · Z-test · p = <0.001 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 47.6 · 95% CI 41.6 to 53.6Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Placebo vs Febuxostat XR 80 mg · Z-test · p = <0.001 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 60.5 · 95% CI 54.6 to 66.3Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 40 mg vs Febuxostat XR 40 mg · Z-test · p = 0.036 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 7.8 · 95% CI -0.5 to 16.1Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.
  • Febuxostat IR 80 mg vs Febuxostat XR 80 mg · Z-test · p = 0.364 (To adjust for multiple comparisons, a closed testing strategy was used. Febuxostat XR 40 and 80 mg were tested separately versus placebo and the corresponding febuxostat IR group at a Bonferroni-corrected significance level of 0.025.) · Difference in proportions: 3.3 · 95% CI -4.9 to 11.6Point estimates, confidence intervals, and p-values are presented using the CHW Z-test which accounts for the interim analysis.

Adverse events

Collected over First dose of double-blind study drug to 30 days past last dose of double-blind study drug (Up to 4 Months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/356 (2.2%)53/356 (14.9%)
Febuxostat IR 40 mg—12/358 (3.4%)53/358 (14.8%)
Febuxostat XR 40 mg—6/355 (1.7%)45/355 (12.7%)
Febuxostat IR 80 mg—8/357 (2.2%)55/357 (15.4%)
Febuxostat XR 80 mg—8/357 (2.2%)38/357 (10.6%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventPlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
Abdominal painGastrointestinal disorders2/3561/3580/3550/3570/357
Acute kidney injuryRenal and urinary disorders1/3561/3580/3552/3570/357
Hypertensive heart diseaseCardiac disorders0/3560/3581/3550/3570/357
Cardiac failure congestiveCardiac disorders0/3561/3581/3550/3571/357
Acute myocardial infarctionCardiac disorders0/3560/3581/3550/3570/357
PneumoniaInfections and infestations1/3561/3581/3550/3570/357
Viral infectionInfections and infestations0/3560/3581/3551/3570/357
Road traffic accidentInjury, poisoning and procedural complications1/3560/3581/3550/3570/357
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/3561/3581/3550/3571/357
AngioedemaSkin and subcutaneous tissue disorders0/3560/3581/3550/3570/357
Most frequent other events
Most frequent other events
EventPlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mg
DiarrhoeaGastrointestinal disorders13/3569/3589/35521/3579/357
HypertensionVascular disorders9/35613/3586/3558/3575/357
NasopharyngitisInfections and infestations11/3567/3587/3559/3574/357
CoughRespiratory, thoracic and mediastinal disorders5/3569/3582/3553/3571/357
Alanine aminotransferase increasedInvestigations6/3567/3588/3552/3574/357
HeadacheNervous system disorders6/3566/3588/3554/3574/357
Upper respiratory tract infectionInfections and infestations4/3566/3586/3555/3578/357
ArthralgiaMusculoskeletal and connective tissue disorders7/3568/3585/3556/3574/357

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.

Age, Continuous
Age, Continuous(years)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
Mean54.4 ± 11.5555.5 ± 11.0755.1 ± 12.6854.9 ± 11.3255.4 ± 11.9355.1 ± 11.71
Age, Customized
Age, Customized(participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
< 45 years7158746861332
45 to < 65 years2232251932192221082
>= 65 years6374887074369
Age, Customized
Age, Customized(participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
18 to < 65 years2942832672872831414
65 to < 85 years6073866973361
>= 85 years312118
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
Female4146434234206
Male3163113123153231577
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
American Indian or Alaska Native120137
Asian2319222325112
Black or African American94891009893474
Native Hawaiian or Other Pacific Islander3543520
White2312352262302251147
Other: Multi-Racial5732623
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
Hispanic or Latino5351614952266
Not Hispanic or Latino3043062943083051517
Region of Enrollment
Region of Enrollment(participants)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
United States3573573553573571783
Height
Height(cm)PlaceboFebuxostat IR 40 mgFebuxostat XR 40 mgFebuxostat IR 80 mgFebuxostat XR 80 mgTotal
Mean175.2 ± 9.95174.8 ± 10.46174.4 ± 10.45174.3 ± 9.42175.3 ± 9.50174.8 ± 9.96

4 further baseline measures are reported on the registry.

08

Study locations

192 sites
  • Binghamton, Alabama, United States
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Gilbert, Arizona, United States
  • Glendale, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Fayetteville, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Searcy, Arkansas, United States
  • Bellflower, California, United States
  • Carmichael, California, United States
  • Costa Mesa, California, United States
  • Covina, California, United States
  • El Cajon, California, United States
  • Encinitas, California, United States
  • Encino, California, United States
  • Escondido, California, United States
  • Gold River, California, United States
  • Irvine, California, United States
  • Lancaster, California, United States
  • Lomita, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Monterey Park, California, United States
  • Murrieta, California, United States
  • North Hollywood, California, United States
  • Norwalk, California, United States
  • Paramount, California, United States
  • Rancho Cucamonga, California, United States
  • Riverside, California, United States
  • Roseville, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Jose, California, United States
  • San Ramon, California, United States
  • Santa Clarita, California, United States
  • Tustin, California, United States
  • Upland, California, United States
  • Arvada, Colorado, United States
  • Westminster, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Lewes, Delaware, United States
  • Boynton Beach, Florida, United States
  • Brandon, Florida, United States
  • Clearwater, Florida, United States
  • Coral Gables, Florida, United States
  • Coral Springs, Florida, United States
  • Daytona Beach, Florida, United States
  • Deland, Florida, United States
  • Doral, Florida, United States
  • Edgewater, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Meyers, Florida, United States
  • Fort Myers, Florida, United States
  • Hialeah, Florida, United States
  • Hollywood, Florida, United States
  • Homestead, Florida, United States
  • Jacksonville, Florida, United States
  • Jupiter, Florida, United States
  • Miami, Florida, United States
  • North Bay Village, Florida, United States
  • Orlando, Florida, United States
  • Pembroke Pines, Florida, United States
  • Pinellas Park, Florida, United States
  • Plant City, Florida, United States
  • Port Charlotte, Florida, United States
  • Sanford, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Columbus, Georgia, United States
  • Dunwoody, Georgia, United States
  • Fort Valley, Georgia, United States
  • Marietta, Georgia, United States
  • Newnan, Georgia, United States
  • Norcross, Georgia, United States
  • Roswell, Georgia, United States
  • Savannah, Georgia, United States
  • Suwanee, Georgia, United States
  • Honolulu, Hawaii, United States
  • Meridian, Idaho, United States
  • Gurnee, Illinois, United States
  • Avon, Indiana, United States
  • Brownsburg, Indiana, United States
  • Newburgh, Indiana, United States
  • Augusta, Kansas, United States
  • Wichita, Kansas, United States
  • Crestview Hills, Kentucky, United States
  • Elizabethtown, Kentucky, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Owensboro, Kentucky, United States
  • Paducah, Kentucky, United States
  • Baker, Louisiana, United States
  • Lafayette, Louisiana, United States
  • Mandeville, Louisiana, United States
  • Metairie, Louisiana, United States

Showing the first 100 of 192 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 Jan;71(1):143-153. doi: 10.1002/art.40685. PubMed 30073793 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year after primary completion. A results delay was requested in Jun 2016.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2014
First posted
May 15, 2014
Start
Apr 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results delay requested
Jun 22, 2016
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02139046
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Apr 2014
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion